How Do I Find an MPN Specialist for Polycythemia Vera?
At a Glance
Patients with Polycythemia Vera can find an MPN specialist through advocacy-group directories and academic or NCI-designated cancer centers. A specialist can confirm the diagnosis, review symptoms and blood counts, and coordinate shared care with a local hematologist.
In this answer
3 sections
Being diagnosed with a rare blood cancer like Polycythemia Vera (PV) can feel isolating, especially if your local care team only sees a few cases a year. Because PV is rare, it is common to seek out an expert in Myeloproliferative Neoplasms (MPNs)—the family of blood cancers that includes PV. While general hematologists and oncologists can provide excellent care for stable PV, an MPN consultation can be invaluable for confirming your diagnosis, managing persistent symptoms, or getting a second opinion [1]. Finding a specialist involves checking MPN advocacy foundations and academic centers, and evaluating doctors based on their specific PV experience, their use of structured symptom tracking, and their willingness to coordinate with your local team.
Important Safety Note: Finding a specialist takes time. Do not wait for a specialist appointment or stop your current medications, aspirin, or phlebotomies (blood draws) on your own. If you develop sudden weakness, trouble speaking, chest pain, severe shortness of breath, a painful or swollen limb, sudden vision changes, or severe abdominal pain, seek emergency medical care immediately, as these can be signs of a serious blood clot.
When an MPN Consultation May Help
A general hematologist is often perfectly equipped to manage uncomplicated PV. However, a specialist consultation is especially useful if there is diagnostic uncertainty, if your blood counts are hard to control, or if you are experiencing difficult symptoms.
- Residual Symptoms and Risks: Real-world observational data show that in routine practice, some PV patients do not reach optimal treatment goals. For example, in one study cohort, more than a third of patients taking hydroxyurea (a commonly used cytoreductive medicine that lowers blood counts) still had a hematocrit (the percentage of blood volume made up of red blood cells) above the recommended 45% [2]. Many also continued to experience fatigue and spleen enlargement. This does not mean hydroxyurea fails in everyone, but a specialist may help if your current plan is not effectively controlling your counts or symptoms [3].
- Clarifying the Diagnosis: Confirming PV requires more than a single genetic test. A specialist will integrate clinical lab results, check your erythropoietin (EPO) levels, and evaluate for a JAK2 mutation [4][5]. They can also rule out “secondary erythrocytosis,” which is a high red blood cell count caused by other factors like smoking, sleep apnea, or low oxygen. Depending on the clinical picture, a bone marrow biopsy may be needed to finalize the diagnosis.
- Complex Complications: If you develop complications, such as a splanchnic vein thrombosis (a blood clot in the veins draining the intestines, liver, or spleen), an expert center can coordinate a multidisciplinary team that includes hepatology or gastroenterology [6][7].
Where to Look for an Expert
You can find MPN specialists through a few key avenues:
- MPN Advocacy Foundations: Organizations like the MPN Research Foundation or MPN Advocacy and Education International often maintain directories of physicians who focus on these rare diseases. However, a directory listing alone does not guarantee current expertise, as surveys show variability in how doctors practice even when listed [8][9].
- Academic Research Centers: Specialists are frequently found at large university research hospitals or National Cancer Institute (NCI) designated cancer centers. These institutions often help translate the newest clinical guidelines into everyday practice [1]. (Note: NCI designation is specific to the United States).
- Shared Care Models: If you do not live near an expert, a “shared care” model may be possible. In this setup, you visit an MPN specialist once or twice a year for a comprehensive review and treatment plan, while your local hematologist handles routine bloodwork, phlebotomies, and urgent issues closer to home. When exploring this, verify who is responsible for acting on abnormal results between visits.
How to Vet a Specialist
When you meet with a potential specialist, focus on how they plan to manage your specific case:
- Check Their Approach to Symptoms: Keeping hematocrit below 45% is crucial to lower clot risk, but symptoms like severe itching (pruritus), fatigue, and night sweats can persist even when blood counts look perfect [3]. A true expert will track your quality of life, sometimes using a structured questionnaire called the MPN-SAF (Symptom Assessment Form) [10].
- Understand Treatment Changes: Your doctor should have a clear plan for what happens if you experience hydroxyurea resistance or intolerance (a clinical assessment meaning the drug stops working effectively, or the side effects become unbearable). Guidelines recommend considering alternative therapies like interferon or ruxolitinib, but these are not interchangeable [11][12]. The choice depends on your age, symptoms, prior clots, and other health factors.
- Ask About Clinical Trials: While a doctor does not have to run clinical trials to provide excellent care, a physician who is involved in MPN research is often highly engaged with the latest scientific evidence and evolving treatments [13].
Common questions in this guide
When should I see an MPN specialist for Polycythemia Vera?
Where can I find a doctor who specializes in Polycythemia Vera?
Can an MPN specialist work with my local hematologist?
What should a Polycythemia Vera specialist monitor besides my blood counts?
What happens if hydroxyurea stops working or causes difficult side effects?
Which Polycythemia Vera symptoms require emergency medical care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which findings—such as hematocrit levels, symptoms, spleen size, or side effects—would lead you to change my treatment plan, and why?
- 2.How many patients with Polycythemia Vera do you actively manage, and are you familiar with current MPN treatment guidelines?
- 3.If we use a shared care model, how will we coordinate with my local hematologist, and who is responsible for reviewing my routine blood tests?
- 4.Do you use a structured questionnaire like the MPN-SAF to track my quality of life, or do you primarily rely on my blood counts?
- 5.How quickly can I contact your team if my symptoms suddenly change or I experience new side effects?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT, Gotlib J, Ali H, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):1033-1062.
PMID: 36075392 - 2
Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review.
Parasuraman S, DiBonaventura M, Reith K, et al.
Experimental hematology & oncology 2015; (5()):3 doi:10.1186/s40164-016-0031-8.
PMID: 26839736 - 3
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
Grunwald MR, Burke JM, Kuter DJ, et al.
Clinical lymphoma, myeloma & leukemia 2019; (19(9)):579-584.e1 doi:10.1016/j.clml.2019.06.001.
PMID: 31303457 - 4
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
Thiele J, Kvasnicka HM, Orazi A, et al.
American journal of hematology 2023; (98(1)):166-179 doi:10.1002/ajh.26751.
PMID: 36200127 - 5
Polycythemia vera.
Ellis MH, Barbui T, Tefferi A
Mayo Clinic proceedings 2026; (101(5)):826-845 doi:10.1016/j.mayocp.2026.01.008.
PMID: 41902804 - 6
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
Amé S, Barraco F, Ianotto JC, et al.
EJHaem 2023; (4(3)):779-791 doi:10.1002/jha2.734.
PMID: 37601853 - 7
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
Finazzi G, De Stefano V, Barbui T
Blood cancer journal 2018; (8(7)):64 doi:10.1038/s41408-018-0100-9.
PMID: 29946154 - 8
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM).
Krecak I, Lucijanic M, Kusec R
Journal of clinical medicine 2025; (14(5)) doi:10.3390/jcm14051524.
PMID: 40094998 - 9
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.
Koren-Michowitz M, Lavi N, Ellis MH, et al.
Annals of hematology 2017; (96(1)):87-92 doi:10.1007/s00277-016-2826-4.
PMID: 27734130 - 10
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Mesa R, Boccia RV, Grunwald MR, et al.
Clinical lymphoma, myeloma & leukemia 2018; (18(9)):590-596 doi:10.1016/j.clml.2018.05.020.
PMID: 30122202 - 11
Moving toward disease modification in polycythemia vera.
Bewersdorf JP, How J, Masarova L, et al.
Blood 2023; (142(22)):1859-1870 doi:10.1182/blood.2023021503.
PMID: 37729609 - 12
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, et al.
Leukemia 2018; (32(5)):1057-1069 doi:10.1038/s41375-018-0077-1.
PMID: 29515238 - 13
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M, Sadjadian P
Expert opinion on pharmacotherapy 2017; (18(18)):1929-1938 doi:10.1080/14656566.2017.1404574.
PMID: 29134817
This page about finding a Polycythemia Vera specialist is for informational purposes only and does not constitute medical advice. Do not stop PV medicines or delay emergency care; discuss referrals and shared care with your hematology team.
Get notified when new evidence is published on Polycythemia vera.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.